CONDENSED CONSOLIDATED STATEMENTS OF SHAREHOLDERS' (DEFICIT) EQUITY (UNAUDITED) - USD ($) $ in Thousands	Total	Common Stock	Accumulated Deficit
Balance, beginning of period at Jan. 28, 2023	$ 29,773	$ 175,450	$ (145,677)
Balance, beginning of period (in shares) at Jan. 28, 2023		12,754,368
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Restricted stock issued (in shares)		86,824
Net share settlement of restricted stock units	(76)	$ (76)
Net share settlement of restricted stock units (in shares)		(28,294)
Stock-based compensation expense	490	$ 490
Net Income (Loss)	(12,107)		(12,107)
Balance, end of period at Apr. 29, 2023	18,080	$ 175,864	(157,784)
Balance, end of period (in shares) at Apr. 29, 2023		12,812,898
Balance, beginning of period at Jan. 28, 2023	29,773	$ 175,450	(145,677)
Balance, beginning of period (in shares) at Jan. 28, 2023		12,754,368
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net Income (Loss)	(37,868)
Balance, end of period at Oct. 28, 2023	$ (7,285)	$ 176,260	(183,545)
Balance, end of period (in shares) at Oct. 28, 2023	12,923,677	12,923,677
Balance, beginning of period at Apr. 29, 2023	$ 18,080	$ 175,864	(157,784)
Balance, beginning of period (in shares) at Apr. 29, 2023		12,812,898
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Restricted stock issued (in shares)		104,475
Stock-based compensation expense	124	$ 124
Net Income (Loss)	(19,364)		(19,364)
Balance, end of period at Jul. 29, 2023	(1,160)	$ 175,988	(177,148)
Balance, end of period (in shares) at Jul. 29, 2023		12,917,373
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Restricted stock issued (in shares)		8,334
Net share settlement of restricted stock units	(5)	$ (5)
Net share settlement of restricted stock units (in shares)		(2,030)
Stock-based compensation expense	277	$ 277
Net Income (Loss)	(6,397)		(6,397)
Balance, end of period at Oct. 28, 2023	$ (7,285)	$ 176,260	(183,545)
Balance, end of period (in shares) at Oct. 28, 2023	12,923,677	12,923,677
Balance, beginning of period at Feb. 03, 2024	$ 3,124	$ 176,552	(173,428)
Balance, beginning of period (in shares) at Feb. 03, 2024	12,926,022	12,926,022
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Restricted stock issued (in shares)		134,597
Net share settlement of restricted stock units	$ (51)	$ (51)
Net share settlement of restricted stock units (in shares)		(21,641)
Stock-based compensation expense	292	$ 292
Net Income (Loss)	(8,830)		(8,830)
Balance, end of period at May. 04, 2024	(5,465)	$ 176,793	(182,258)
Balance, end of period (in shares) at May. 04, 2024		13,038,978
Balance, beginning of period at Feb. 03, 2024	$ 3,124	$ 176,552	(173,428)
Balance, beginning of period (in shares) at Feb. 03, 2024	12,926,022	12,926,022
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net Income (Loss)	$ (31,014)
Balance, end of period at Nov. 02, 2024	$ (27,132)	$ 177,310	(204,442)
Balance, end of period (in shares) at Nov. 02, 2024	13,117,942	13,117,942
Balance, beginning of period at May. 04, 2024	$ (5,465)	$ 176,793	(182,258)
Balance, beginning of period (in shares) at May. 04, 2024		13,038,978
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Restricted stock issued (in shares)		72,660
Stock-based compensation expense	264	$ 264
Net Income (Loss)	(14,504)		(14,504)
Balance, end of period at Aug. 03, 2024	(19,705)	$ 177,057	(196,762)
Balance, end of period (in shares) at Aug. 03, 2024		13,111,638
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Restricted stock issued (in shares)		8,334
Net share settlement of restricted stock units (in shares)		(2,030)
Stock-based compensation expense	253	$ 253
Net Income (Loss)	(7,680)		(7,680)
Balance, end of period at Nov. 02, 2024	$ (27,132)	$ 177,310	$ (204,442)
Balance, end of period (in shares) at Nov. 02, 2024	13,117,942	13,117,942